|
|
Blood, 15 April 2006, Vol. 107, No. 8, pp. 3339-3341.
Prepublished online as a Blood First Edition Paper on December 13, 2005; DOI 10.1182/blood-2005-09-3917.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Brief report
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
Amy V. Jones,
Richard T. Silver,
Katherine Waghorn,
Claire Curtis,
Sebastian Kreil,
Katerina Zoi,
Andreas Hochhaus,
David Oscier,
Georgia Metzgeroth,
Eva Lengfelder,
Andreas Reiter,
Andrew J. Chase, and
Nicholas C. P. Cross
From the Wessex Regional Genetics Laboratory, Salisbury, United Kingdom; the Human Genetics Division, University of Southampton, United Kingdom; Weill Medical College of Cornell University, New York, NY; the Foundation of Biomedical Research of Academy of Athens, Greece; III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Heidelberg, Germany; and Royal Bournemouth Hospital, Bournemouth, United Kingdom.
Imatinib and recombinant interferon alpha (rIFN ) can induce remission in polycythemia vera (PV) patients, but gauging the depth of responses has not been possible due to lack of a specific disease marker. We found that patients undergoing imatinib (n = 14) or rIFN (n = 7) therapy remained strongly positive for V617F JAK2, although there was a significant reduction in the median percentage of mutant alleles that correlated with hematologic response (P = .001). Furthermore, individuals who achieved complete hematologic remission had lower levels of V617F than those who did not (P = .001). Of 9 imatinib-treated cases for whom pretreatment samples were available, 7 with no or partial hematologic responses showed a marginal increase (median, 1.2-fold; range, 1.0-1.5) in the percentage of V617F alleles on treatment, whereas the 2 patients who achieved complete hematologic remission showed a 2- to 3-fold reduction. Our data indicate that, although PV patients may benefit from imatinib or rIFN, molecular responses are relatively modest.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Quintas-Cardama, H. Kantarjian, T. Manshouri, R. Luthra, Z. Estrov, S. Pierce, M. A. Richie, G. Borthakur, M. Konopleva, J. Cortes, et al.
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
J. Clin. Oncol.,
November 10, 2009;
27(32):
5418 - 5424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cankovic, L. Whiteley, R. C. Hawley, R. J. Zarbo, and D. Chitale
Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory: Evaluation of Screening and Quantitation Methods
Am J Clin Pathol,
November 1, 2009;
132(5):
713 - 721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, P. Guglielmelli, and A. Tefferi
Advances in Understanding and Management of Myeloproliferative Neoplasms
CA Cancer J Clin,
May 1, 2009;
59(3):
171 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Theocharides, J. R. Passweg, M. Medinger, R. Looser, S. Li, H. Hao-Shen, A. S. Buser, A. Gratwohl, A. Tichelli, and R. C. Skoda
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders
Haematologica,
December 1, 2008;
93(12):
1890 - 1893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Larsen, M. B. Moller, K. de Stricker, P. Norgaard, J. Samuelsson, C. Marcher, O. W. Bjerrum, M. T Andersen, and H. C. Hasselbalch
Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses.
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
1744 - 1744.
[Abstract]
|
|
|
|
|
|
|
J.-J. Kiladjian, B. Cassinat, S. Chevret, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, B. Grandchamp, C. Chomienne, and P. Fenaux
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Blood,
October 15, 2008;
112(8):
3065 - 3072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ricksten, L. Palmqvist, P. Johansson, and B. Andreasson
Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia
Haematologica,
August 1, 2008;
93(8):
1260 - 1261.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Helbig, B. Stella-Holowiecka, M. Majewski, M. Lewandowska, and J. Holowiecki
Interferon {alpha} induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation
Haematologica,
November 1, 2007;
92(11):
e118 - e119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Finazzi and T. Barbui
How I treat patients with polycythemia vera
Blood,
June 15, 2007;
109(12):
5104 - 5111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Chen, P. Lu, A. V. Jones, N. C.P. Cross, R. T. Silver, and Y. L. Wang
Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders
J. Mol. Diagn.,
April 1, 2007;
9(2):
272 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu, and Z. J. Zhao
Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth
J. Biol. Chem.,
February 9, 2007;
282(6):
3428 - 3432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Wolstencroft, K. Hanlon, L. W. Harries, G. R. Standen, A. Sternberg, and S. Ellard
Development of a Quantitative Real-Time Polymerase Chain Reaction Assay for the Detection of the JAK2 V617F Mutation
J. Mol. Diagn.,
February 1, 2007;
9(1):
42 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kroger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe, M. Bornhauser, A. Reiter, T. Zabelina, A. R. Zander, and B. Fehse
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
Blood,
February 1, 2007;
109(3):
1316 - 1321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Illmer, M. Schaich, G. Ehninger, C. Thiede, and on behalf of the DSIL2003 AML study group
Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias
Haematologica,
January 1, 2007;
92(1):
137 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and R. E. Richard
Myeloproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
172 - 227.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Campbell and A. R. Green
The Myeloproliferative Disorders
N. Engl. J. Med.,
December 7, 2006;
355(23):
2452 - 2466.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hoffman
Searching for polycythemia vera's Holy Grail
Blood,
September 15, 2006;
108(6):
1792 - 1793.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Kiladjian, B. Cassinat, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, M.-L. Menot, G. Massonnet, J.-L. Dutel, K. Ghomari, et al.
High molecular response rate of polycythemia vera patients treated with pegylated interferon {alpha}-2a
Blood,
September 15, 2006;
108(6):
2037 - 2040.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Levine and G. Wernig
Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders
Hematology,
January 1, 2006;
2006(1):
233 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era
Hematology,
January 1, 2006;
2006(1):
240 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
